Skip to Main Content

Paper Details

Ovarian cancer mutational processes drive site-specific immune evasion.
Nature
49
2022
BRCA1, BRCA2, CD8, CD8 T cells, HGSOC, HLA, HRD-Del (BRCA2 mutant-like) tumours, High-grade serous ovarian cancer, Homologous recombination-deficient HRD-Dup (BRCA1 mutant-like) and, Ovarian cancer, TGF, adnexal tumours, cancer, foldback, naive/stem-like and memory T cells, patients, peritoneal, single, tumour, whole
Author NameAffiliation
Diljot GrewalMemorial Sloan Kettering Cancer Center
Arnaud Da Cruz PaulaMemorial Sloan Kettering Cancer Center
Ritika KundraMarie-Josee and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center
Agnes VialeMarie-Josee and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center
Daniel W KellyMemorial Sloan Kettering Cancer Center
Jianjiong GaoMemorial Sloan Kettering Cancer Center
Jianjiong GaoMarie-Josee and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center
Jianjiong GaoMemorial Sloan Kettering Cancer Center
Jianjiong GaoMarie-Josee and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center
Andrea SchietingerWeill Cornell Medical Center
Andrea SchietingerMemorial Sloan Kettering Cancer Center
Travis J HollmannMemorial Sloan Kettering Cancer Center
Travis J Hollmann
Robert A SoslowMemorial Sloan Kettering Cancer Center
Lora H EllensonMemorial Sloan Kettering Cancer Center
Andrew McPhersonMemorial Sloan Kettering Cancer Center
Britta WeigeltMemorial Sloan Kettering Cancer Center
  • 1 - 17

Datasets

Release 1.2